[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Luz MA, Kotb AF, Aldousari S, Brimo F, Tanguay S, Kassouf W, Aprikian AG: Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol; 2010;8:97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.
  • BACKGROUND: Retroperitoneal lymph node dissection has been advocated for the management of post-chemotherapy (PC-RPLND) residual masses of non-seminomatous germ cell tumors of the testis (NSGCT).
  • Between 1994 and 2008, three surgeons operated 73 patients with residual masses after cisplatin-based chemotherapy for a metastatic testicular cancer.
  • Patients needed to have normal postchemotherapy serum tumor markers, no prior surgical attempts to resect retroperitoneal masses and resectable retroperitoneal tumor mass at surgery to be included in this analysis RESULTS: Mean age was 30.4 years old.
  • The mean size of retroperitoneal metastasis was 6.3 and 4.0 cm, before and post-chemotherapy, respectively.
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / surgery. Retroperitoneal Space. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1998 Aug;25(3):479-84 [9728217.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2):203-9 [9562453.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1235-40 [17665498.001]
  • [Cites] J Urol. 2009 May;181(5):2097-101; discussion 2101-2 [19286227.001]
  • [Cites] Health Rep. 2009 Mar;20(1):7-19 [19388364.001]
  • [Cites] Urol Oncol. 2009 Jul-Aug;27(4):417-21 [19573772.001]
  • [Cites] BJU Int. 2009 Nov;104(9 Pt B):1404-12 [19840021.001]
  • [Cites] Urol Oncol. 2010 Sep-Oct;28(5):504-9 [19097812.001]
  • [Cites] J Urol. 2001 May;165(5):1517-20 [11342909.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1668-76 [11920527.001]
  • [Cites] BJU Int. 2002 Apr;89(6):549-56 [11942962.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):843-7 [12644820.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1329-34 [8055456.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):976-80 [7853586.001]
  • [Cites] J Urol. 1995 Oct;154(4):1373-5 [7544838.001]
  • [Cites] J Urol. 1996 Nov;156(5):1656-8 [8863564.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):843-7 [9291803.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1409-19 [9762943.001]
  • (PMID = 21062470.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Nonseminomatous germ cell tumor
  • [Other-IDs] NLM/ PMC2991320
  •  go-up   go-down


2. Zuo CJ, Wang PJ, Shao CW, Wang MJ, Tian JM, Xiao Y, Ren FY, Hao XY, Yuan M: CT-guided percutaneous ethanol injection with disposable curved needle for treatment of malignant liver neoplasms and their metastases in retroperitoneal lymph nodes. World J Gastroenterol; 2004 Jan;10(1):58-61
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT-guided percutaneous ethanol injection with disposable curved needle for treatment of malignant liver neoplasms and their metastases in retroperitoneal lymph nodes.
  • AIM: To explore the feasibility of computed tomography (CT)-guided percutaneous ethanol injection (PEI) using a disposable curved needle for treatment of malignant liver neoplasms and their metastases in retroperitoneal lymph nodes.
  • METHODS: CT-guided PEI was conducted using a disposable curved needle in 26 malignant liver tumors smaller than 5 cm in diameter and 5 lymph node metastases of liver cancer in the retroperitoneal space.
  • The disposable curved needle was composed of a straight trocar (21G) and stylet, a disposable curved tip (25 G) and a fine stylet.
  • For relatively large malignant liver tumors, multi-point injection was carried out for a better distribution of the ethanol injected throughout the masses.
  • The curved needle was also used for treatment of the metastasis in retroperitoneal lymph nodes blocked by blood vessels and inaccessible by the straight needle.
  • In 5 patients with metastases of liver cancer in retroperitoneal lymph nodes who received 1 to 3 times of PEI, all the foci treated were completely necrotic and smaller demonstrated by dynamic contrast-enhanced CT or MRI 3 months later.
  • CONCLUSION: CT-guided PEI using a disposable curved needle is effective, time-saving and convenient, providing an alternative therapy for the treatment of malignant liver tumors and their retroperitoneal lymph node metastases.
  • [MeSH-major] Ethanol / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Solvents / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Nodes. Lymphatic Metastasis. Male. Middle Aged. Needles. Retroperitoneal Space. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14695769.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Solvents; 3K9958V90M / Ethanol
  • [Other-IDs] NLM/ PMC4717079
  •  go-up   go-down


3. Janetschek G: Laposcopic retroperitoneal lymph node dissection: evolution of a new technique. World J Urol; 2000 Sep;18(4):267-71
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laposcopic retroperitoneal lymph node dissection: evolution of a new technique.
  • Retroperitoneal lymph node dissection is the most accurate method of detecting occult lymph node metastases in the retroperitoneum.
  • [MeSH-major] Laparoscopy. Lymph Node Excision / methods. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Quality of Life. Retroperitoneal Space. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11000309.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 30
  •  go-up   go-down


Advertisement
4. Seeber S, Strumberg D: [Metastases with CUP syndrome]. Urologe A; 2006 May;45(5):614-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases with CUP syndrome].
  • [Transliterated title] Metastasen mit unbekanntem Primärtumor (CUP).
  • At the time point of first diagnosis of CUP syndrome, usually more than 80% of the patients present a disseminated situation.
  • For patients presenting with metastasis to peripheral lymph nodes, node dissection may be curative.
  • In patients with small cell malignancies, peritoneal carcinomatosis (in women), poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum, but without metastases to viscera or bone, objective long-term responses are possible with combination chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / drug therapy. Palliative Care / methods. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / secondary
  • [MeSH-minor] Clinical Trials as Topic. Humans. Neoplasm Recurrence, Local / prevention & control. Practice Guidelines as Topic. Practice Patterns, Physicians'. Quality of Life. Syndrome. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Jan 1;57(1):120-4 [3940611.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):47-58 [12667308.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):210-4 [2302061.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):205-11 [11856596.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1720-5 [7541451.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):425-31 [11407517.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2035-9 [3046543.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Anticancer Res. 1993 Sep-Oct;13(5A):1619-23 [8239543.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):206-28 [8503017.001]
  • [Cites] Cancer Res. 1989 Aug 1;49(15):4311-5 [2743318.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5092-4 [15107816.001]
  • [Cites] Onkologie. 2001 Feb;24(1):38-43 [11441279.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Bull Cancer. 2001 Jun;88(6):619-27 [11459709.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1160-6 [9506364.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] J Pathol. 2001 Sep;195(1):41-52 [11568890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):143-7 [10758316.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1605-9 [11822762.001]
  • [Cites] Ugeskr Laeger. 2001 Mar 5;163(10):1432-6 [11257752.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):273-8 [8503023.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2056-66 [9164218.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):147-52 [11884050.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):43-8 [12542974.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3611-3 [12552964.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Wien Klin Wochenschr. 1989 Jul 14;101(14):464-72 [2672606.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1073-7 [12475531.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • (PMID = 16710679.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 40
  •  go-up   go-down


5. Sendler A, Strumberg D, Tannapfel A: [Carcinoma of unknown primary site (CUP syndrome)]. Chirurg; 2008 Jul;79(7):689-95; quiz 696
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the growing array of sophisticated diagnostic tools for establishing a diagnosis of human neoplasia, 2-6% of all cancer patients still present metastatic cancer of which detailed investigations fail to identify the primary anatomic site.
  • At the time of first diagnosis with carcinoma of unknown primary site, usually more than 80% of patients present with dissemination.
  • Node dissection may be curative for patients with metastases to peripheral lymph nodes.
  • Objective long-term response is possible in combination with chemotherapy in patients with small-cell malignancies, peritoneal carcinomatosis (in women), or poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum but without metastases to viscera or bone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):47-58 [12667308.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):205-11 [11856596.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):425-31 [11407517.001]
  • [Cites] Onkologie. 2001 Feb;24(1):38-43 [11441279.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1605-9 [11822762.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):147-52 [11884050.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3611-3 [12552964.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1073-7 [12475531.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • [Cites] Urologe A. 2006 May;45(5):614-9 [16710679.001]
  • (PMID = 18584137.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Hara H, Igarashi A, Yano Y, Yashiro T, Ueno E, Aiyoshi Y: Interventricular methotrexate therapy for carcinomatous meningitis due to breast cancer: a case with leukoencephalopathy. Breast Cancer; 2000;7(3):247-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had had a radical mastectomy for left breast cancer 10 years earlier, and 6 months prior to presentation she completed CMF chemotherapy for treatment of retroperitoneal metastasis.
  • CT and MRI to identify potential causes of the paraplegia and lumbago showed leptomeningeal carcinomatosis due to dissemination from invasive recurrence of the retroperitoneal tumor.
  • Although administration of prednisolone mostly resolved her symptom, the patient died 9 months after the diagnosis of carcinomatous meningitis.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / secondary. Leukoencephalitis, Acute Hemorrhagic / chemically induced. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Methotrexate / adverse effects. Retroperitoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11029806.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M: An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clin Exp Metastasis; 2004;21(1):7-12
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer.
  • In order to investigate the antitumor and antimetastatic efficacy of new chemotherapeutic agents, a novel, red-fluorescent, orthotopic model of pancreatic cancer was constructed in nude mice.
  • Fluorescent tumor fragments were then transplanted onto the pancreas by surgical orthotopic implantation (SOI), facilitating high-resolution, real-time visualization of tumor and metastatic growth and dissemination in vivo.
  • Tumor growth at the primary site was visible within the first postoperative week, while distant metastasis and the development of ascites became visible over the following week.
  • This MIA-PaCa-2-RFP model produced extensive local disease and metastases to the retroperitoneum (100%), spleen (100%), intestinal and periportal lymph nodes (100%), liver (40%) and diaphragm (80%), and gave rise to malignant ascites and peritoneal carcinomatosis in 80% of cases.
  • Growth and metastasis of tumor was more rapid and frequent than in previously described orthotopic pancreatic cancer models, leading to a median survival of only 21 days after tumor implantation.
  • This unique, red fluorescent model rapidly and reliably simulates the highly aggressive course of human pancreatic cancer and can be easily non-invasively visualized in the live animal.
  • [MeSH-major] Luminescent Proteins / metabolism. Neoplasm Metastasis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Male. Mice. Mice, Nude. Neoplasm Transplantation. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1206-11 [10655509.001]
  • [Cites] Pancreas. 2000 Mar;20(2):152-7 [10707930.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):546-56 [12217792.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):969-73 [10504696.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5645-9 [1608975.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):627-30 [8391244.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2288-92 [9622060.001]
  • [Cites] Surgery. 1999 Sep;126(3):562-7 [10486610.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Pancreas. 2001 Oct;23(3):227-35 [11590317.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1534-40 [11888932.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5713-9 [8971180.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):213-8 [11315094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3824-9 [11891294.001]
  • (PMID = 15065597.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23100-1851; United States / PHS HHS / / R43-89779
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / red fluorescent protein
  •  go-up   go-down


8. Okayama S, Matsui M, Somekawa S, Iwano M, Saito Y: Non-contrast MRI for the evaluation of hydronephrotic and dysfunctioning kidney secondary to testicular cancer. Ren Fail; 2009;31(2):153-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-contrast MRI for the evaluation of hydronephrotic and dysfunctioning kidney secondary to testicular cancer.
  • Gadolinium-containing magnetic resonance imaging (MRI) contrast agents have been reported to induce nephrogenic systemic fibrosis in patients with renal dysfunction, and therefore their use has been restricted.
  • However, even without contrast agents, MRI can provide much valuable information on the pathophysiology of renal diseases.
  • This report describes the case of a 90-year-old man with a hydronephrotic and dysfunctioning right kidney induced by testicular cancer evaluated by non-contrast MRI.
  • Moreover, a retroperitoneal metastatic tumor was detected adjacent to the right kidney, which appeared to constrict the right urinary duct.
  • These findings clarified that the retroperitoneal metastasis from the right testicular cancer led to hydronephrosis and dysfunctioning of the right kidney.
  • [MeSH-major] Contrast Media / contraindications. Hydronephrosis / diagnosis. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212914.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


9. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL: Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol; 2003 Jun;169(6):2113-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?
  • PURPOSE: We identified a subset of patients with bladder cancer (transitional cell carcinoma) and regional nodal metastasis to the retroperitoneal lymph nodes without detectable systemic dissemination.
  • We report the results of a phase II study exploring the potential benefit of retroperitoneal lymph node dissection in patients with transitional cell carcinoma of the bladder in whom disease has shown a significant response to chemotherapy.
  • MATERIALS AND METHODS: A total of 11 patients with biopsy proven metastatic transitional cell carcinoma in the retroperitoneal lymph nodes and no evidence of visceral metastatic disease in whom disease showed a significant response to chemotherapy underwent complete bilateral retroperitoneal lymph node dissection.
  • The end point of study was disease specific survival, calculated from the time of retroperitoneal lymph node dissection to death from transitional cell carcinoma of the bladder.
  • RESULTS: Four patients underwent delayed retroperitoneal lymph node dissection.
  • Seven patients underwent concurrent cystectomy, and pelvic and retroperitoneal lymph node dissection.
  • Nine patients had evidence of residual disease in the retroperitoneal nodes.
  • One patient with retrocrural recurrence attained a complete response to salvage chemotherapy and remained disease-free 57 months after retroperitoneal lymph node dissection.
  • We stratified the patients based on the number of involved lymph nodes at retroperitoneal lymph node dissection and noted that viable tumor in no more than 2 lymph nodes correlated with greater disease specific and recurrence-free survival (p = 0.006 and 0.01, respectively).
  • CONCLUSIONS: Retroperitoneal lymph node dissection can be safely performed for metastatic transitional cell carcinoma.
  • Retroperitoneal lymph node dissection has curative potential, particularly in patients with viable tumor in no more than 2 lymph nodes after chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / secondary. Lymph Node Excision. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Humans. Lymphatic Metastasis. Retroperitoneal Space. Survival Rate

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771730.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement